These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Use of extrusion aids for successful production of Kollidon® CL-SF pellets by extrusion-spheronization. Loka NC, Saripella KK, Pinto CA, Neau SH. Drug Dev Ind Pharm; 2018 Apr; 44(4):632-642. PubMed ID: 29183166 [Abstract] [Full Text] [Related]
4. The influence of chitosan and sodium alginate and formulation variables on the formation and drug release from pellets prepared by extrusion/spheronisation. Chatchawalsaisin J, Podczeck F, Newton JM. Int J Pharm; 2004 May 04; 275(1-2):41-60. PubMed ID: 15081137 [Abstract] [Full Text] [Related]
5. Multiple batch manufacturing of theophylline pellets using the wet-extrusion/spheronization process with κ-carrageenan as pelletisation aid. Krueger C, Thommes M. Pharm Dev Technol; 2013 Feb 04; 18(1):225-35. PubMed ID: 22780876 [Abstract] [Full Text] [Related]
6. Properties of pellets manufactured by wet extrusion/spheronization process using kappa-carrageenan: effect of process parameters. Thommes M, Kleinebudde P. AAPS PharmSciTech; 2007 Nov 09; 8(4):E95. PubMed ID: 18181555 [Abstract] [Full Text] [Related]
9. Extruder scale-up assessment in the process of extrusion-spheronization: comparison of radial and axial systems by a design of experiments approach. Désiré A, Paillard B, Bougaret J, Baron M, Couarraze G. Drug Dev Ind Pharm; 2013 Feb 09; 39(2):176-85. PubMed ID: 23216219 [Abstract] [Full Text] [Related]
12. Comparison between a twin-screw extruder and a rotary ring die press. Part II: influence of process variables. Schmidt C, Kleinebudde P. Eur J Pharm Biopharm; 1998 Mar 09; 45(2):173-9. PubMed ID: 9704914 [Abstract] [Full Text] [Related]
14. Investigations on the influence of the type of extruder for pelletization by extrusion-spheronization. I. Extrusion behavior of formulations. Thoma K, Ziegler I. Drug Dev Ind Pharm; 1998 May 09; 24(5):401-11. PubMed ID: 9876602 [Abstract] [Full Text] [Related]
15. Multivariate optimization of formulation and process variables influencing physico-mechanical characteristics of site-specific release isoniazid pellets. Pund S, Joshi A, Vasu K, Nivsarkar M, Shishoo C. Int J Pharm; 2010 Mar 30; 388(1-2):64-72. PubMed ID: 20035851 [Abstract] [Full Text] [Related]
17. Analysis of particle kinematics in spheronization via particle image velocimetry. Koester M, Thommes M. Eur J Pharm Biopharm; 2013 Feb 30; 83(2):307-14. PubMed ID: 23000404 [Abstract] [Full Text] [Related]
18. Properties of drug-containing spherical pellets produced by a hot-melt extrusion and spheronization process. Young CR, Koleng JJ, McGinity JW. J Microencapsul; 2003 Feb 30; 20(5):613-25. PubMed ID: 12909545 [Abstract] [Full Text] [Related]
19. [Formulation and process optimization of formula Qiqi pellets prepared by extrusion-spheronization]. Chen HX, Jia XB, Chen Y, Pan GL, Cheng XD. Zhongguo Zhong Yao Za Zhi; 2006 Nov 30; 31(22):1862-5. PubMed ID: 17285984 [Abstract] [Full Text] [Related]
20. Influence of MCC II fraction and storage conditions on pellet properties. Krueger C, Thommes M, Kleinebudde P. Eur J Pharm Biopharm; 2013 Nov 30; 85(3 Pt B):1039-45. PubMed ID: 23872176 [Abstract] [Full Text] [Related] Page: [Next] [New Search]